Browsing: TALENEdited

Cemacabtagene ansegedleucel (cema-cel, formerly ALLO-501A) is being evaluated in the Phase II ALPHA3 trial in patients who respond to first-line chemoimmunotherapy but remain positive for minimal residual disease. At day 45, plasma circulating tumour DNA had decreased by a median of 97.7 per cent with cema-cel, versus a 26.6 per cent increase under observation. No…